Aiforia Gets CE-IVD Marks for Breast Cancer Test, Cloud-Based Clinical Software

Finland-based Aiforia Technologies has received CE-IVD marks for two in vitro diagnostics products — an image analysis software product for identifying progesterone receptors (PR) in breast cancer patients and a cloud-based viewer.

The majority of breast cancer cases express estrogen receptors (ER) and/or PR, which are considered the most significant biomarkers for evaluating patients. The company recently received a CE-IVD mark for ER version of its test.

The Aiforia Clinical AI Model for Breast Cancer (PR) automates the detection of tumors from slide images as well as identifying areas with high PR-positive density, or hotspots.

The cloud-based viewer is intended to improve clinical workflows for pathologists.